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Chapter 1
Introduction and outline 




Chronic inflammatory bowel diseases (IBD) comprising Crohn’s disease (CD) and ulcerative 
colitis (UC) are characterized by chronic relapsing inflammation of the gastrointestinal tract. 
The combined prevalence of CD and UC is estimated at 100 – 200 / 100.000 in developed 
countries. The pathogenesis of IBD is only partially understood but concordance rates in 
twins and siblings suggest that a genetic predisposition, apart from environmental and im-
munological factors, contributes to the pathogenesis of IBD. In the past decade, tremendous 
progress has been achieved in unraveling the genetic etiology of IBD. By conducting genome 
wide scans, several susceptibility loci for IBD have been identified. In 2001 the CARD15 gene 
encoding for the NOD2 protein on chromosome 16 (IBD1) has been found to be strongly asso-
ciated with CD susceptibility.1  NOD2 is part of the innate immune system and is an intracellu-
lar pathogen-associated molecular pattern (PAMP) receptor that recognizes specific bacterial 
membrane components. Two missense mutations (R702W and G908R) and one frameshift 
insertion mutation (L1007fsinsC) in the leucine rich repeat region of the protein are inde-
pendently associated with ileal CD in Caucasian patients. The L1007fsinsC mutation causes 
a truncated protein, suggesting that a defect in bacterial recognition might be involved in 
CD.  The exact mechanism how mutations in CARD15 are involved in IBD susceptibility is still 
only partially understood and studies thus far give conflicting data. Although the discovery 
of CARD15 as a susceptibility gene has not led to clinical consequences, important progress 
and insight in the pathogenesis of IBD has been made. Actually, the discovery of the CARD15 
gene in IBD has been one of the success stories in genetic research in complex genetic dis-
eases and it has helped researchers to focus at signaling pathways of bacterial products in 
both epithelial and immune cells in the gut. Since CD and UC have many different phenotypic 
presentations and genome wide scans detected several linkage regions, IBD is considered a 
polygenic disease. Therefore many additional candidate-gene studies have been performed 
in the last decade. 
CODE Study
For genetic research in complex genetic disorders as IBD it is important to have large ho-
mogenous cohorts of well described patients. In 2001 the CODE study (Chronische Ontsteking 
van de Darm en Erfelijkheid: Chronic Inflammation of the Gut and Inheritance) started in 
the University Medical Center Groningen. DNA has been, and is still being collected to form 
a large cohort of mainly Caucasian patients and family members from the Northern part of 
the Netherlands. Since the immigration rate in the Northern part of the Netherlands has 
been relatively low, this cohort can be considered a founder population. It is therefore suit-
able for genetic research and in particular for haplotype analysis, since it is assumed that the 
present population descends from a limited number of founders that results in evolutionary 
conserved haplotypes. Previously, several association studies have been performed in this 
cohort. For CARD15 the R702W and the 1007fsinsC mutation were independently associated 
with CD and not with UC. For different subsets of CD, association was found for an early age 
of onset, ileal localization, familial occurrence of IBD and penetrating or stricturing disease 
behavior.2  In another study in collaboration with the University Medical Center Nijmegen and 
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the Erasmus Medical Center Rotterdam association analysis was performed for IBD and Toll 
Like Receptor 4 (TLR4). TLR4 is, like NOD2, part of the innate immune system and is involved 
in NF-κB regulation. Haplotype analysis showed an association of CD and UC with TLR4, but 
in contrast with prior publications, no association could be found for the Asp266Gly and the 
Thr399Ile polymorphisms and IBD.3 Furthermore a candidate gene study was carried out for 
association of IBD and the Multi Drug Resistant 1 (MDR1) Gene, but no association could be 
found with IBD, CD, UC or different subsets of patients. 4
Genotypes vs. Phenotypes
An important aspect in studying IBD genetics is the consequent description of disease phe-
notypes.  Since IBD is considered a multigenic disorder, different genes are probably involved 
in different subsets of phenotypes. It is therefore mandatory to have internationally accepted 
classification systems for IBD. An accepted and frequently used system is the Vienna clas-
sification.5 It includes age of onset, disease localisation and disease behaviour. A number of 
studies, including a study from the CODE cohort has validated this classification. However, 
several considerations have led to an update of the Vienna classification system during an 
expert meeting in Montreal in 2005. The main modifications were the introduction of an 
early age of onset category (< 16 years), the possibility of co-classification of upper gastroin-
testinal involvement and the inclusion of perianal disease as a disease modifier instead of 
being a form of penetrating disease. For the current thesis the original Vienna classification 
has been used. 
Phar macogenetics
Pharmacogenetics is another research subject in IBD genetics. There has been much interest 
in the pharmacogenetics of azathioprine metabolism. Azathioprine is a purine analogue that 
is frequently used in the treatment of Crohn’s disease but its use is hampered by the frequent 
occurrence of side-effects. Polymorphisms in the thiopurinemethyltransferase (TPMT) gene, 
which metabolizes azathioprine to 6-mercaptopurine and 6-methyl-mercaptopurine, and 
inosine triphosphate pyrophospatase (ITP-ase) deficiency which leads to accumulation of the 
metabolite 6-thio-ITP, have been found to be responsible for a subset of the side-effects of 
azathioprine therapy.  
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Aims and outline of  the thesis
This thesis aims to gain insight in the genetic background of IBD.
The first part of this thesis focuses on specific genetic associations with IBD. Therefore, a 
detailed review of the current literature on IBD-genetics is given in Chapter 2. Since the 
discovery of the association of CARD15 and IBD, many additional genes have been studied. 
Several of these genes are potentially truly associated, but results have been conflicting for 
many of the associations found. Next to specific genetic associations, current research on the 
functional role of mutations in CARD15 in IBD is also reviewed. 
The initial part of the thesis comprises two studies investigating novel candidate genes 
for IBD susceptibility.  In chapter 3 the association between IBD and Interleukin Receptor 
associated Kinase-M (IRAK-M) is studied. IRAK-M is a NF- κB -mediated, negative regulator 
of Toll-like receptor (TLR) signaling and is localized on chromosome 12q14, a susceptibil-
ity locus for IBD. It was hypothesized that a functional mutation in a negative regulator 
of TLR signaling might induce impaired endotoxin tolerance and increased inflammatory 
responses. Therefore IRAK-M is a good candidate gene for association analysis with IBD. 542 
patients with IBD (309 CD and 233 UC) and 305 controls were studied. Phenotypic details 
of all CD patients according to the Vienna classification were available. UC patients were 
phenotyped according to an accepted classification including extend of the disease, age 
of onset, need for colectomy, extraintestinal manifestations and the occurrence of malig-
nancy. Two single nucleotide polymorphisms (SNPs) and six microsattelite markers were 
evaluated by association analysis and Haplotype Sharing Statistics. Results were stratified 
for CARD15 mutations R702W, G908R and 1007fsinsC.  
In Chapter 4 the genetic association between RUNX3 and IBD is studied. RUNX3 is a mem-
ber of the runt domain family of transcription factors. It is known that loss of RUNX3 
function is associated with a spontaneous colitis in knockout mice. It is a member of the 
TGF- ß signaling pathway, which is a potent inhibitor of inflammation in IBD. Impaired 
activation of RUNX3 might result in decreased activity of the TGF- ß pathway and decreased 
inhibition of inflammation in IBD.The gene encoding for RUNX3 resides on chromosome 
1p36, which is a susceptibility locus for IBD. Therefore RUNX3 is a good candidate gene for 
susceptibility for IBD.  Four SNPs and four microsattelite markers were studied for RUNX3 
in the CODE cohort.  Furthermore, mutations in SLC22A4 and 5 encoding for the organic 
cation transporters 1 and 2 (OCTN1/2) were found to be associated with CD in previous 
publications and an association was found between polymorphisms in SLC22A4, resulting 
in a disrupted binding site for RUNX in rheumatoid arthritis.6 For that reason, association 
analysis for 6 SNPs in SLC22A4/5 (including the known polymorphisms 207 G→C, 1672 C→
G) and IBD and interaction with RUNX3 was studied. All results were stratified for CARD15 
status. In addition to the genetic association analysis RUNX3 and OCTN1 expression was 
analyzed in colonic and ileal, inflamed and non-inflamed mucosal tissue samples of 30 
IBD patients and 6 controls. 
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The second part of the thesis comprises three studies aimed at the confirmation of previously 
described genetic associations with IBD and describes specific genotype-phenotype interac-
tions. Next to CARD15, SLC22A4/5 and TLR4, several other genes have been identified to be as-
sociated with IBD susceptibility. Simultaneously with the identification of SLC22A4/5, genetic 
variations in DLG5 (Drosophila Discs Large Homologue 5) on chromosome 10q23 showed as-
sociation with CD.7 DLG5 is important in maintaining epithelial stability and genetic variants 
could result in an impaired intestinal permeability.  Additionally, two recent important stud-
ies identified two novel CD associated genes by performing the first genome wide association 
studies.8 9  An uncommon coding SNP in the gene encoding for the interleukin-23 receptor 
(IL23R) conferred strong protection against CD. It was also shown to be associated with UC in 
non-Jewish patients. The other SNP in the autophagy-related 16-like 1 gene (ATG16L1) was 
shown to be associated with CD.
It is supposed that genetic susceptibility has a more prominent role in the aetiology of early-, 
than of late-onset IBD, since early-onset patients were less exposed to environmental factors 
than late-onset patients. As a result, a higher frequency of IBD associated mutations is ex-
pected. In chapter 5 polymorphisms of CARD15, TLR4, SLC22A4/5 and DLG5 are analyzed in 
a cohort of 103 pediatric onset and 696 adult onset IBD patients and controls. Prevalence of 
mutations in the pediatric cohort was compared with the prevalence in adult-onset IBD and 
controls. Specific genotype-phenotype associations were studied. 
Since it is of pivotal importance that genetic associations are confirmed in independent 
cohorts from different countries, chapter 6 describes a replication study for the two most 
strongly associated SNPs in IL23R and ATG16L1 in our cohort of IBD patients. We were also 
interested in discovering whether these two genes are more generally involved in other com-
mon chronic disorders of the gastrointestinal tract and we therefore included a cohort of 
celiac disease patients from the Netherlands. 
It is not only mandatory that previously found associations are confirmed in independent co-
horts, these cohorts also need to have sufficient power to detect specific genotype-phenotype 
interactions. For SLC22A4/5 and DLG5 there have been conflicting results in the literature, but 
many studies are hampered by small sample size or the lack of adequate uniform phenotypic 
descriptions. As mentioned before, for genetic research in complex genetic disorders as IBD it 
is important to have large homogenous cohorts of well described and uniformly phenotyped 
patients. For that reason a large nationwide collaborative project was initiated. Results are 
described in chapter 7. DNA samples and phenotypic details of IBD patients from seven Uni-
versity Medical Centers in the Netherlands (University Medical Center Groningen; Academic 
Medical Center, Amsterdam; VU University Medical Center, Amsterdam; Leiden University 
Medical Center; Radboud University Nijmegen Medical Center; Erasmus Medical Center, Rot-
terdam and the University Medical Center Utrecht ) were collected. 2937 patients (1696 CD, 
1099 UC and 142 with indeterminate colitis) and 1484 healthy controls were included. Phe-
notypic details were available for 2090 patients (1315 CD / 775 UC).  We performed an associa-
tion analysis for DLG5, SLC22A4/5 and ATG16L1 with IBD, CD, UC en different subsets of CD and 
UC. Interaction between these genes was studied.
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The last part of the thesis focuses on azathioprine toxicity. In daily clinical practice it was 
noted that azathioprine toxicity occurred more often in IBD compared to other diseases for 
which azathioprine is frequently used. Particularly azathioprine induced pancreatitis had 
been rarely observed in other diseases than Crohn’s disease in clinical practice as well as in 
the literature. To investigate this clinical observation, a retrospective case-note review has 
been performed analyzing azathioprine toxicity and necessity of withdrawal in 1564 patients 
with a liver or renal transplantation, systemic lupus erythematosus, Wegener’s granuloma-
tosis, autoimmune hepatitis, rheumatoid arthritis ulcerative colitis or Crohn’s disease. Aza-
thioprine use and toxicity in the University Medical Center Groningen were also compared to 
the use in IBD patients in a large community hospital (Martini Hospital Groningen).  Results 
are described in chapter 8. The fact that azathioprine induced acute pancreatitis was more 
prevalent in Crohn’s disease compared to other diseases, led to the exploration of an associa-
tion of azathioprine induced pancreatitis and circulating pancreatic antibodies, which are 
highly specific for CD compared to UC and other autoimmune diseases. 
Finally the results of the studies in this thesis are summarized and future perspectives for 




1. Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with 
susceptibility to Crohn’s disease. Nature. 2001;411:599-603. 
2. Oostenbrug LE, Nolte IM, Oosterom E et al. CARD15 in inflammatory bowel disease and Crohn’s 
disease phenotypes: an association study and pooled analysis. Dig Liver Dis. 2006;38:834-45. 
3. Oostenbrug LE, Drenth JP, de Jong DJ et al. Association between Toll-like receptor 4 and 
inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:567-75. 
4. Oostenbrug LE, Dijkstra G, Nolte IM et al. Absence of association between the multidrug resistance 
(MDR1) gene and inflammatory bowel disease. Scand J Gastroenterol. 2006;41:1174-82. 
5. Gasche C, Scholmerich J, Brynskov J et al. A simple classification of Crohn’s disease: report of the 
Working Party for the World Congresses of  Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 
2000;6:8-15. 
6. Peltekova VD, Wintle RF, Rubin LA et al. Functional variants of OCTN cation transporter genes are 
associated with Crohn’s disease.Nat Genet. 2004;36:471-5.
7. Stoll M, Corneliussen B, Costello CM et al. Genetic variation in DLG5 is associated with 
inflammatory bowel disease. Nat Genet. 2004;36:476-80.
8. Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an 
inflammatory bowel disease gene. Science. 2006;314:1461-3. 
9. Hampe J, Franke A, Rosenstiel P et al. A genome-wide association scan of nonsynonymous SNPs 
identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet. 2007;39:207-211. 

